Portfolio Companies – Page 35 – BioScience Managers

Destiny Pharma announces research collaboration with Aston University to investigate new XF-platform drug candidates

17th July 2018/in Destiny Pharma

Research to investigate potential antimicrobial candidates against biofilms Brighton, United Kingdom – 17 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today announces it has signed a three-year research collaboration agreement with Aston University. The […]

Adherium Announces Patient Program with Connecticut Children’s Medical Center to Explore Best Practices for Access to Better Asthma Care Nationally

10th July 2018/in Adherium

10 Jul 2018 San Mateo, CA – July 10, 2018: Adherium (ASX: ADR), a leading digital health company that improves medication adherence and patient outcomes, today announced a patient program with Connecticut Children’s Medical Center to help patients with asthma manage their condition with Adherium’s technology, the Hailie™ solution. Connecticut Children’s Medical Center’s close work with the […]

AVITA Medical Announces Acquisition of Manufacturing Facility to Support Planned U.S. Launch of RECELL® Device

28th June 2018/in Avita Medical

Valencia, Calif., USA, and Melbourne, Australia, 28 June 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that it has entered into an agreement to acquire a manufacturing facility to support the planned U.S. launch of the RECELL® Autologous Cell Harvesting Device in the treatment of burns. The facility is currently operated by a […]

Destiny Pharma notes FDA statement on their focus to enable new approaches to fight AMR

14th June 2018/in Destiny Pharma

Brighton, United Kingdom – 14 June 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), notes the FDA Commissioner, Scott Gottlieb M.D.’s further announcements this week outlining the regulator’s support of new incentives for companies developing novel […]

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

8th June 2018/in Armata Pharmaceuticals

“These case studies indicate that AB-SA01 may be safely administered intravenously in the critically ill and may have a role to play in the management of severe staphylococcal sepsis, for patients with resistant and life-threatening infections” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for […]

AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference

7th June 2018/in Armata Pharmaceuticals

PUBLIC COMPANY INFORMATION: “Furthermore, treatment with AB-PA01 was safe and well-tolerated. In this case study, bacteriophage therapy has demonstrated to hold much promise for patients with cystic fibrosis suffering from multidrug resistant pulmonary bacterial infections.” AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today […]

Scientific Advisory Board

30th May 2018/in Destiny Pharma

Destiny Pharma has a Scientific Advisory Board (SAB) of key opinion leaders in relevant fields to help guide and inform the future clinical development of the XF platform. Our SAB includes the following members: David Roblin MD FRCP FFPM FMedSci (SAB Chairman) Professor David Roblin is President of Research and Development at Summit Therapeutics. David […]

AmpliPhi Biosciences to Present at 5th World Congress on Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018

18th May 2018/in Armata Pharmaceuticals

riday, May 18, 2018 6:50 am EDT SAN DIEGO PUBLIC COMPANY INFORMATION: “We are delighted to participate in TID 2018 and to share our product development experience and clinical perspective on the promise of phage therapeutics as a potential treatment for combatting increasing, and potentially life-threatening, antibiotic resistance” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: […]

Adherium’s Technology Used for Large Scale Electronic Data Capture in Landmark Mild-Asthma Trials

18th May 2018/in Adherium

18 May 2018 San Mateo, CA – May 18, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, announced the extensive use of it’s Hailie™(previously known as Smartinhaler™) technology in two landmark clinical trials investigating the treatment of mild asthma, which have just been published in the New England Journal […]

Adherium Launches the Hailie™ Global Brand to Connect People with Asthma and COPD to Better Care

17th May 2018/in Adherium

17 May 2018 San Mateo, CA – May 16th, 2018: Adherium (ASX: ADR), an award-winning digital health company that improves medication adherence, patient outcomes and engagement, today announced the launch of the Hailie™ global brand to connect people with asthma and COPD to better care. The launch is a rebrand of the existing Smartinhaler™ brand, and […]